AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02702726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with coconut gel
Description: 25g coconut oleogel
Study NCT02702726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with coconut oil
Description: 25g coconut oil
Study NCT02702726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with sunflower gel
Description: 25g sunflower oleogel
Study NCT02702726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Congee and juice with sunflower oil
Description: 25g sunflower oil
Study NCT03260231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milled seed mix
Description: Dietary intervention with or without seed mix
Study NCT03092895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Study NCT03092895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally every day with a dose escalation
Study NCT03092895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Subjects receive FOLFOX4 treatment every 2 weeks
Study NCT03092895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: Subjects receive GEMOX treatment every 2 weeks
Study NCT02216643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
Study NCT02216643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stentriever Solitaire FR® or Penumbra System®
Description: Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
Study NCT05847725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic bandaging
Description: The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally.
Study NCT05847725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short stretch bandaging
Description: Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.
Study NCT05847725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
Study NCT01244776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular corneal matrix
Description: Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
Study NCT01174160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vernakalant hydrochloride
Description: Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
Study NCT01174160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to vernakalent hydrochloride
Description: Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
Study NCT03832634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fetal Genome Profiling.
Description: Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
Study NCT04146415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spect scan with mTc99-PYP
Description: . About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
Study NCT02799953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-based self-management model
Description: Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
Study NCT01274585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation (PTNS)
Description: Stimulation using PTNS device for 30 minutes weekly for 12 weeks
Study NCT01274585 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Posterior tibial nerve stimulation
Description: Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
Study NCT01247571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT02630888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
Study NCT02630888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU (400 mg/m\^2) will be administered as an IV bolus, followed by 2400 mg/m\^2 by continuous IV infusion over 46 (± 1) hours, q2w.
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 will be administered IV over 120 (± 5) minutes q2w.
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
Study NCT02715531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as 80 mg/m\^2 IV over 120 minutes q3w (Group E2).
Study NCT02723409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Round Procedure Umbilicoplasty
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure
Study NCT02723409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scarless round procedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure
Study NCT02723409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted U Procedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure
Study NCT02723409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inverted VProcedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure
Study NCT02723409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y deepithelialized Procedure
Description: Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure
Study NCT00679653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 10 mg, capsules, once daily
Study NCT00679653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine
Description: 8-wks, sibutramine, 15 mg, capsules, once daily
Study NCT00679653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil/trandolapril
Description: 2 wk Run-in phase, antihypertensive therapy only
Study NCT00679653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol/HCT
Description: 2 wk Run-in phase, antihypertensive therapy only
Study NCT00679653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: felodipine/ramipril
Description: 2 wk Run-in phase, antihypertensive therapy only
Study NCT02441166 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mastocytosis diagnosis
Description: Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
Study NCT02695641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25mg bevacizumab
Description: Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
Study NCT02695641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.50mg bevacizumab
Description: Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
Study NCT00427336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 by vein daily over 30 minutes
Study NCT00427336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 by vein daily over 2 hours
Study NCT00427336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: 3.75 mg/kg by vein daily over 4 hours
Study NCT03278951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Group
Study NCT03278951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Person Group
Study NCT01746680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus with Methotrexate
Description: Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
Study NCT00454389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epi-Rad90™ Ophthalmic System
Description: A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
Study NCT00454389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
Study NCT03717948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR Exercise
Description: Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
Study NCT03717948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTL Exercise
Description: Participants will exercise on a recumbent bike placed on flat ground (CTL).
Study NCT03072277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosa Hexaenoic Acid (DHA)
Description: 400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
Study NCT03072277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
Study NCT03539341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH-Thailand parenting programme
Description: Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
Study NCT03539341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control (care as usual)
Description: The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
Study NCT04136665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Adapted program
Description: 6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
Study NCT03603028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Mixed Reality Gaming for Chronic Low Back Pain
Study NCT04826211 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
Study NCT01037244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study NCT01037244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study NCT03680404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Phenylephrine)
Description: This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
Study NCT03680404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine + Apocynin
Description: This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
Study NCT03680404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine + Allopurinol
Description: This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
Study NCT03680404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine + Tempol
Description: This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
Study NCT02851082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training program
Description: Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases.
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: anaesthetic
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: anaesthetic
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfentanyl
Description: anaesthetic
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfentanyl
Description: anaesthetic
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: anaesthetic
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: anaesthetic
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local anaesthetics
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anaesthetics
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: local anaesthetics
Study NCT03086213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anaesthetics
Study NCT03355170 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lansoprazole/Domperidone
Description: Experimental
Study NCT03355170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Active comparator
Study NCT04557605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive cycling exercise test to exhaustion
Description: Progressive step cycling exercise test to exhaustion
Study NCT04557605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive cycling exercise test to exhaustion
Description: Progressive step cycling exercise test to exhaustion
Study NCT01844245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
Study NCT01562457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
Study NCT01874860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline capsule, 100 mg, taken twice daily
Study NCT01874860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream
Description: Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
Study NCT01874860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
Study NCT01874860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
Study NCT01874860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Recommended for daily use if rash returns (Topical cream)
Study NCT01874860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medrol-dose pack (Steroid)
Description: Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
Study NCT01038063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Study NCT01038063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination